- Guide to PHARMACOLOGY
Molecular properties generated using the CDK
|Guide to Malaria Pharmacology Comments|
|P218 was selected from a structure-informed drug discovery process to develop inhibitors of the clinically validated target P. falciparum dihydrofolate reductase (PfDHFR) . The compound is example 8 from patent WO2009048957 .
Potential Target/Mechanism Of Action: P218 potentially inhibits both wild-type and clinically relevant mutated forms of PfDHFR.
|Target Candidate Profiles|
|Profile||Intended Use||Target Stage||Comment||References|
|TCP-1||reduce parasite burden||asexual blood stages|